Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ARMO Initiates Phase I trial of AM0010 | Contract Pharma

What are you searching for?

Sign in

ARMO Initiates Phase I trial of AM0010

Will establish safety and tolerability in patients with advanced solid tumors

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ARMO BioSciences has initiated the first cohort of patients with advanced solid tumors in a Phase I trial of AM0010, a PEGylated form of recombinant human interleukin-10 (IL-10). Based on clinical and preclinical data, ARMO plans to develop the drug for indications including cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. 

The Phase I trial is designed to establish the safety and tolerability of AM0010 in patients with advanced solid tumors. The company will also explore anti-tumor and biomarker responses to determine dose and potential patient stratification. The trial will enroll patients at four locations in the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters